secwatch / observer

8-K filed February 10, 2026, 6:59 PM ET ticker NKTR CIK 0000906709

other material confidence high sentiment positive materiality 0.75

Nektar REZOLVE-AD maintenance data show durable EASI-75/90, vIGA-AD responses

NEKTAR THERAPEUTICS

71% (monthly) and 83% (quarterly) maintained EASI-75 on 24 µg/kg; 85% and 63% maintained vIGA-AD 0/1.
EASI-100 increased 2-5 fold: from 4% to 22% (monthly) and 9% to 18% (quarterly) in re-randomized patients.
Discontinuation rate due to AEs was 3.5%; injection site reactions mostly mild; no new safety concerns.
FDA alignment on Phase 3 design: 24 µg/kg Q2W induction, co-primary endpoints; start Q2 2026.
New responses at Week 52: 51% new EASI-75 (monthly) and 39% (quarterly) support prolonged therapy.

item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-043755
form_type: 8-K
ticker: NKTR
cik: 0000906709
company_name: NEKTAR THERAPEUTICS
filed_at: 2026-02-10T23:59:59+00:00
discovered_at: 2026-05-14T18:02:38.001636+00:00
generated_at: 2026-05-16T03:46:11.178873+00:00
sec_items: ["7.01", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-043755
json_url: https://secwatch.observer/filing/0001193125-26-043755.json
markdown_url: https://secwatch.observer/filing/0001193125-26-043755.md
text_url: https://secwatch.observer/filing/0001193125-26-043755.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/906709/000119312526043755/0001193125-26-043755-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/906709/000119312526043755/d103279d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

CSR

Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City

CENTERSPACE June 1, 2026, 4:30 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

DBX

Dropbox secures $400M revolving credit facility, authorizes $900M share repurchase program

DROPBOX, INC. June 1, 2026, 9:06 AM ET other_material Items 1.01, 2.03, 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

NXTC

NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027

NextCure, Inc. June 1, 2026, 8:10 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

JBIO

Jade Biosciences reports Phase 1 interim data: JADE101 shows ~70% IgA reduction, favorable safety, differentiated PK

Jade Biosciences, Inc. June 1, 2026, 7:55 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

EIKN

Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel

Eikon Therapeutics, Inc. June 1, 2026, 7:30 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

MVIS

MicroVision seeks reverse stock split approval; ratio 1:5 to 1:15; annual meeting July 10, 2026

MICROVISION, INC. June 1, 2026, 5:02 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

AIB

Blockchain Digital signs 15-yr, 65 MW electric agreement at CLT-01; 25 MW LOIs in pipeline

BlockchAIn Digital Infrastructure, Inc. June 1, 2026, 4:57 PM ET other_material Items 1.01, 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-26-043755

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.